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13 months after initial surgery the patient complained of generalized pain, but could not elaborate further. There were no abnormal findings on clinical examination. A limited whole-body scan (LWB) FDG PET/CT demonstrated a FDG-avid mass in the left masseter muscle (Figure 1 ). The corresponding CT showed no abnormal findings. The lesion was not palpable. The patient underwent surgery and histopathology confirmed metastasis.
The patient was without symptoms, but a routine LWB PET/CT five months later showed a soft tissue tumor in close proximity of the left sciatic nerve (Figure 2) . Furthermore, the patient developed a swollen red right ankle and magnetic resonance imaging (MRI) scan hereof showed a lesion in the distal end of the fibula suspicious of metastasis. Biopsies confirmed metastatic lesions in both sites. An extended whole-body (TWB) PET/CT scan in February 2013 showed progression of disease with additional multiple subcutaneous metastases, and an osteolytic lesion in the sternum. Immunotherapy with interferon alfa-2b, pegylated (PEG-Intron) and interleukin (IL)-2 and later ipilimumab were given.
A PET/CT thirteen months after immunotherapy was started demonstrated progression with multiple new cutaneous metastases ( Figure 3 ). Treatment with adoptive cell therapy using tumorinfiltrating lymphocytes (TIL therapy) was started.
1 This personalized immunotherapy is based on preconditioning chemotherapy followed by infusion of autologous tumor-infiltrating lymphocytes (TIL) and T cell growth factor interleukin-2 (IL-2). 1,2 The patient had a cutaneous metastasis excised from which TILs were isolated, cultured, expanded and concentrated for treatment. Following preconditioning lymphodepleting chemotherapy with cyclophosphamide and fludarabine a single treatment with infusion of TIL followed by IL-2 infusion was given. An evaluation PET/CT scan 4 months after TIL therapy showed regression of the disease. The PET/CT 24 months after TIL therapy showed complete-remission ( Figure 4 ). The patient remains well and is reviewed every six months with PET/CT with the latest PET/CT 2.5 years after TIL therapy still showing complete-remission.
Discussion
Our case demonstrates isolated intramuscular metastases as the first sign of metastatic disease in a patient with known melanoma. In a study by Surov et al. skeletal muscle metastases in patients with metastatic cancer were diagnosed incidentally in the majority (76.3%) of patients during routine staging CT examinations. 3 Among patients with metastatic melanoma, skeletal muscle metastases were prevalent in 3.6%. 3 The increased use of PET/CT allows the detection of skeletal muscle metastases that would previously have remained undetected. 4 PET/CT is superior for the detection of distant metastases in both the staging and surveillance of melanoma patients. 5 Nguyen et al. showed that a significant percentage of soft tissue metastases (46%) occurred outside the limited whole-body field of view. 6 Similarly, the LWB PET/CT of our patient did not diagnose the bone metastasis in the distal end of the fibula. A true whole-body PET/CT does allow for a more accurate staging, restaging with therapeutic and prognostic implications for the patients. 6, 7 Until recently, the one-year survival rate for stage IV patients with M1c disease was 33%. 8 However, a new era of systemic therapy has led to significant improvements in overall survival suggesting that some patients may be cured. 9 Evidence exists that current therapeutic options for metastatic disease are more effective if the disease is treated with a lower disease burden. 10, 11 Hence, melanoma metastases must be diagnosed early in order to maximize the chances of patient survival. . PET/CT 24 months after adoptive cell therapy using tumor-infiltrating lymphocytes TIL therapy was started showed complete-remission.
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